(Q46417845)

English

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

T J de Villiers

1

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

A A Chines

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

S Palacios

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

P Lips

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

A Z Sawicki

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

A B Levine

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

C Codreanu

7

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

N Kelepouris

8

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

J P Brown

9

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

language of work or name

0 references

publication date

10 June 2010

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

Osteoporosis International

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

22

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

567-576

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

https://scigraph.springernature.com/pub.10.1007/s00198-010-1302-6

0 references

Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Burden of osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

The search for the ideal SERM.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Designing the ideal selective estrogen receptor modulator--an achievable goal?

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Benefit-risk assessment of raloxifene in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1302-6

21 January 2018

Epidemiology of osteoporotic fractures

1 reference

https://pubmed.ncbi.nlm.nih.gov/20535606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene

1 reference

https://pubmed.ncbi.nlm.nih.gov/20535606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective estrogen receptor modulators: an update on recent clinical findings

1 reference

https://pubmed.ncbi.nlm.nih.gov/20535606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emerging drugs for postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20535606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteoporotic fractures: mortality and quality of life.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20535606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse events reported by postmenopausal women in controlled trials with raloxifene

1 reference

https://pubmed.ncbi.nlm.nih.gov/20535606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20535606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00198-010-1302-6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/20535606

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46417845&oldid=2110437747"